Beyond Doomsday Fears: Why We Need to Consider the Potential Harms of AI Psychotherapy

There is increased enthusiasm about the use of Artificial Intelligence (AI) technologies in psychotherapy. Notably, AI psychotherapy chatbots are increasing in popularity, especially since the US Food and Drug Administration (FDA) gave one of these apps breakthrough device designation. This article raises concerns about the lack of consideration of potential harms of this technology for clinical trial participants, and current and future users. We outline what these harms might be, by turning to the Belmont Report and the existing literature on harms of (typical) psychotherapy and conclude with two recommendations. Note that our goal is not to articulate doomsday fears regarding the use of AI in psychotherapy contexts; rather we offer a constructive proposal in thinking about the potential harms of these tools and invite clinicians, patients, developers, researchers, policymakers and funding agencies to work together to augment the benefits of these tools and minimize their potential harms.

Authors

Institutions

Publication Details

Journal
The American Journal of Bioethics
Published
2025-02-06
DOI
https://doi.org/10.1080/15265161.2025.2457724
Citations
20
Primary Topic
Neuroethics, Human Enhancement, Biomedical Innovations
Type
article
Field-Weighted Citation Impact
28.62
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Beyond Doomsday Fears: Why We Need to Consider the Potential Harms of AI Psychotherapy

Megan Delehanty, Şerife Tekin
20 citations
The American Journal of Bioethics
Neuroethics, Human Enhancement, Biomedical Innovations
28.62
article

Beyond Doomsday Fears: Why We Need to Consider the Potential Harms of AI Psychotherapy

Megan Delehanty, Şerife Tekin
article en
20 citations

Abstract

There is increased enthusiasm about the use of Artificial Intelligence (AI) technologies in psychotherapy. Notably, AI psychotherapy chatbots are increasing in popularity, especially since the US Food and Drug Administration (FDA) gave one of these apps breakthrough device designation. This article raises concerns about the lack of consideration of potential harms of this technology for clinical trial participants, and current and future users. We outline what these harms might be, by turning to the Belmont Report and the existing literature on harms of (typical) psychotherapy and conclude with two recommendations. Note that our goal is not to articulate doomsday fears regarding the use of AI in psychotherapy contexts; rather we offer a constructive proposal in thinking about the potential harms of these tools and invite clinicians, patients, developers, researchers, policymakers and funding agencies to work together to augment the benefits of these tools and minimize their potential harms.

The American Journal of BioethicsVol. 26(2)
University of Calgary (CA), SUNY Upstate Medical University (US)
Openalex Percentile: Top 0%
Neuroethics, Human Enhancement, Biomedical Innovations
28.62
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.